Lampalizumab
Also known as: Anti-CFD Fab, Anti-factor D, F-125, FCFD4514S, LFG316, RG7417
Source Lampalizumab at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lampalizumab is a humanized Fab antibody fragment targeting complement factor D, investigated for treatment of geographic atrophy secondary to age‑related macular degeneration.
Mechanism of Action
Binds and inhibits complement factor D, blocking the alternative complement pathway and reducing inflammation in the retina
Routes of Administration
Goals & Uses
- Geographic atrophy (AMD)OphthalmologyModerate
- Visual acuity preservation in geographic atrophyFunctional OutcomesLow
- Reduction of geographic atrophy lesion growthOphthalmology / Retinal DiseaseLow
- Complement pathway inhibition in AMDMechanistic / PharmacologicalModerate
Contraindications
- Active intraocular inflammationInflammatoryModerate
- Severe intraocular inflammationOcularModerate
- Hypersensitivity to lampalizumab or any excipientImmunologicHigh
- Ocular or periocular infectionInfectiousHigh
- Active ocular infectionOphthalmologyHigh
Adverse Effects
- Increased intraocular pressureOcularRare
- Retinal detachmentOcularRare
- Conjunctival hemorrhageOcularCommon
- Intraocular inflammationOcularUncommon
- Vitreous floatersOcularCommon
- EndophthalmitisOcular / InfectiousRare
- Susceptibility to encapsulated bacterial infectionsImmunologic / InfectiousUnknown
Drug Interactions
- Other intravitreal agents (e.g., anti‑VEGF)Moderate
- Other complement inhibitorsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeAbsolute
- Patients with systemic complement deficienciesImmunologicRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalDevelopment halted; no EMA approval.
- United StatesInvestigationalPhase III trial failed; no FDA approval.
- United KingdomInvestigationalNo approval; program discontinued globally in 2018.
Phase III trials failed to meet primary endpoints; development discontinued. No regulatory approval in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Lampalizumab?
Lampalizumab is a humanized Fab antibody fragment targeting complement factor D, investigated for treatment of geographic atrophy secondary to age‑related macular degeneration.
What is Lampalizumab used for?
Lampalizumab is educationally associated with: Geographic atrophy (AMD), Visual acuity preservation in geographic atrophy, Reduction of geographic atrophy lesion growth, Complement pathway inhibition in AMD. Educational only — not medical advice.
How is Lampalizumab administered?
Recorded routes of administration: Intravitreal.
What are the potential side effects of Lampalizumab?
Reported adverse effects include: Increased intraocular pressure, Retinal detachment, Conjunctival hemorrhage, Intraocular inflammation, Vitreous floaters, Endophthalmitis, Susceptibility to encapsulated bacterial infections. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lampalizumab?
Recorded contraindications: Active intraocular inflammation, Severe intraocular inflammation, Hypersensitivity to lampalizumab or any excipient, Ocular or periocular infection, Active ocular infection. Consult a qualified clinician before use.